JP2022525193A - Prpf31遺伝子発現ノックダウンによる、インビトロで分化したヒト細胞の生存の改善 - Google Patents

Prpf31遺伝子発現ノックダウンによる、インビトロで分化したヒト細胞の生存の改善 Download PDF

Info

Publication number
JP2022525193A
JP2022525193A JP2021555433A JP2021555433A JP2022525193A JP 2022525193 A JP2022525193 A JP 2022525193A JP 2021555433 A JP2021555433 A JP 2021555433A JP 2021555433 A JP2021555433 A JP 2021555433A JP 2022525193 A JP2022525193 A JP 2022525193A
Authority
JP
Japan
Prior art keywords
cells
differentiated
nucleic acid
agent
vitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525193A5 (cg-RX-API-DMAC7.html
Inventor
チャールズ イー. マリー
サラ デュプラ
ジョン ラマッチア
ジェームス フガテ
ウィリアム ロブ マクレラン
リル パボン
スコット ティース
洋 土田
ステファニー エイ. タック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of JP2022525193A publication Critical patent/JP2022525193A/ja
Publication of JP2022525193A5 publication Critical patent/JP2022525193A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021555433A 2019-03-15 2020-03-13 Prpf31遺伝子発現ノックダウンによる、インビトロで分化したヒト細胞の生存の改善 Pending JP2022525193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818979P 2019-03-15 2019-03-15
US62/818,979 2019-03-15
PCT/US2020/022679 WO2020190739A1 (en) 2019-03-15 2020-03-13 Improved survival of human cells differentiated in vitro by prpf31 gene expression knockdown

Publications (2)

Publication Number Publication Date
JP2022525193A true JP2022525193A (ja) 2022-05-11
JP2022525193A5 JP2022525193A5 (cg-RX-API-DMAC7.html) 2023-03-17

Family

ID=72520464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555433A Pending JP2022525193A (ja) 2019-03-15 2020-03-13 Prpf31遺伝子発現ノックダウンによる、インビトロで分化したヒト細胞の生存の改善

Country Status (7)

Country Link
US (1) US20220152278A1 (cg-RX-API-DMAC7.html)
EP (1) EP3937956A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022525193A (cg-RX-API-DMAC7.html)
CN (1) CN113710258A (cg-RX-API-DMAC7.html)
AU (1) AU2020241251A1 (cg-RX-API-DMAC7.html)
CA (1) CA3129782A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020190739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4356931A4 (en) * 2021-06-16 2025-07-16 Chigenovo Co Ltd VARIANT OF PRPF31 AND ITS USE
US20250082689A1 (en) * 2021-07-21 2025-03-13 University Of Washington Compositions and methods for enhancing cardiomyocyte transplant engraftment
WO2024086352A2 (en) * 2022-10-21 2024-04-25 Biogen Ma Inc. Compositions and methods for treating retinitis pigmentosa

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166288A1 (en) * 2006-01-19 2007-07-19 University Of Washington Formulation to improve survival of transplanted cells
JP2011512326A (ja) * 2007-12-31 2011-04-21 ナノコア セラピューティクス,インコーポレイテッド 心不全の治療用のrna干渉
WO2011072247A2 (en) * 2009-12-11 2011-06-16 The Brigham And Women's Hospital, Inc. Pathogen restriction factors
JP2018511652A (ja) * 2015-03-06 2018-04-26 マサチューセッツ アイ アンド イヤー インファーマリー Prpf31遺伝子における変異により引き起こされる遺伝性網膜変性に対する遺伝子増強療法
WO2018078301A1 (fr) * 2016-10-28 2018-05-03 Université Pierre Et Marie Curie - Paris 6 (Upmc) Procédé de différenciation de cellules souches pluripotentes en cardiomyocytes
WO2018170280A1 (en) * 2017-03-15 2018-09-20 University Of Washington Methods and compositions for enhancing cardiomyocyte maturation and engraftment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
AU2008204541B2 (en) * 2007-01-09 2014-07-10 Lead Pharma Cel Models Ip B.V. Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
DK3421601T3 (da) * 2011-12-30 2020-02-24 Cellscript Llc Fremstilling og anvendelse af in-vitro-syntetiseret ssRNA til indføring i pattedyrceller med henblik på at inducere en biologisk eller biokemisk effekt

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166288A1 (en) * 2006-01-19 2007-07-19 University Of Washington Formulation to improve survival of transplanted cells
JP2011512326A (ja) * 2007-12-31 2011-04-21 ナノコア セラピューティクス,インコーポレイテッド 心不全の治療用のrna干渉
WO2011072247A2 (en) * 2009-12-11 2011-06-16 The Brigham And Women's Hospital, Inc. Pathogen restriction factors
JP2018511652A (ja) * 2015-03-06 2018-04-26 マサチューセッツ アイ アンド イヤー インファーマリー Prpf31遺伝子における変異により引き起こされる遺伝性網膜変性に対する遺伝子増強療法
WO2018078301A1 (fr) * 2016-10-28 2018-05-03 Université Pierre Et Marie Curie - Paris 6 (Upmc) Procédé de différenciation de cellules souches pluripotentes en cardiomyocytes
WO2018170280A1 (en) * 2017-03-15 2018-09-20 University Of Washington Methods and compositions for enhancing cardiomyocyte maturation and engraftment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PORMEHR, LEILA AZIZZADEH ET AL.: "Human organotypic retinal fl at-mount culture (HORFC) as a model for retinitispigmentosa11", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. Volume 119, Issue 8, JPN6024002935, 10 May 2018 (2018-05-10), pages 6775 - 6783, ISSN: 0005247216 *

Also Published As

Publication number Publication date
WO2020190739A1 (en) 2020-09-24
EP3937956A1 (en) 2022-01-19
US20220152278A1 (en) 2022-05-19
EP3937956A4 (en) 2022-12-28
AU2020241251A1 (en) 2021-10-07
CA3129782A1 (en) 2020-09-24
CN113710258A (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
US12492400B2 (en) Compositions and methods for induced tissue regeneration in mammalian species
JP2023026679A (ja) ヒストンh3-リジントリメチル化を除去することによって体細胞核移入(scnt)効率を増加させるための方法および組成物
US20210180013A1 (en) Improved methods for inducing tissue regeneration and senolysis in mammalian cells
US8815593B2 (en) Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling
US20240368541A1 (en) Methods of generating mature corneal endothelial cells
US20250216377A1 (en) Compositions and methods for detecting cardiotoxicity
JP2011522520A (ja) 細胞の脱分化を行う方法
US20220152278A1 (en) Improved survival of human cells differentiated in vitro by prpf31 gene expression knockdown
US20130202649A1 (en) Activation of innate immunity for nuclear reprogramming of somatic cells
JP2022534395A (ja) 細胞リプログラミングのための組成物および方法
WO2017177050A1 (en) Direct reprogramming of somatic cells into myogenic cells
US20240392252A1 (en) Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
CN117940558A (zh) 用于细胞重编程的方法和组合物
US20200306296A1 (en) Induced tissue regeneration using extracellular vesicles
US12173322B2 (en) Genome-edited induced pluripotent stem cells, and cells derived therefrom, and uses thereof
US20250059505A1 (en) Improved methods for inducing the maturation of mammalian cells
HK40096970A (en) Methods of generating mature corneal endothelial cells
Sottile Mesenchymal stem cells generate distinc functional hybrids via cell fusion or entosis
Buccini Cardiogenic differentiation of induced pluripotent stem cells for regeneration of the ischemic heart
HK40007852B (en) Method for generating mesoderm and/or endothelial colony forming cell-like cells having in vivo blood vessel forming capacity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230309

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240827